Moderna Shares Drop After Cancer Drug Leak

Moderna investors watched shares tumble today after early trial numbers leaked to the public. Wall Street often sells first and asks questions later when surprises hit the tape.

The drugmaker later released the full study for its cancer shot. The official numbers beat market targets. Still, the early confusion pushed the stock down during regular trading.

Wild swings happen fast in biotech stocks. Smart investors look past daily noise and focus on long-term patient progress. Science moves forward even when early trading gets messy.

Source: CNBC